ADC Therapeutics Makes Strategic Employee Inducement Grant to Enhance Workforce Engagement

On July 1, 2026, ADC Therapeutics SA (NYSE: ADCT), a prominent leader in the field of antibody-drug conjugates (ADCs), unveiled its decision to grant stock options as an inducement to a new employee. This grant encompasses a total of 17,000 options to purchase shares of the company's common stock, marking a vital step in enhancing the motivation and performance of the workforce. Through this strategic initiative, ADC Therapeutics aims to reward and inspire its employees to contribute meaningfully to the company’s success.

The grant was sanctioned by the Compensation Committee of the Company’s Board of Directors in accordance with the company’s Inducement Plan. This plan is specifically designed to attract leading talent while encouraging high levels of productivity and loyalty among staff members. ADCT is leveraging the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08, which lays the foundation for such grants aimed at promising new talent.

The structure of the grant is designed to ensure a long-term commitment from the employee. Specifically, 25% of the granted shares will vest on the first anniversary of the grant date. Following that milestone, the remaining 75% will vest at a monthly rate of 1/48th of the total shares, leading to complete vesting by the fourth anniversary of the grant’s initiation, contingent upon ongoing employment with the company. This thoughtful vesting schedule incentivizes sustained performance and dedicated service.

About ADC Therapeutics

ADC Therapeutics is at the forefront of innovation in cancer treatment, specifically with its flagship product, ZYNLONTA® (loncastuximab tesirine-lpyl), which has been a game-changer for patients suffering from certain types of lymphomas. The FDA granted accelerated approval to ZYNLONTA, which is currently being utilized for patients battling relapsed or refractory diffuse large B-cell lymphoma post multiple lines of systemic therapy. The company is also exploring further development opportunities for ZYNLONTA, including investigating potential combinations with other therapeutic agents.

Headquartered in Lausanne, Switzerland, and with a robust operational presence in New Jersey, ADC Therapeutics excels in advancing its ADC platform from clinical trials to full-scale manufacturing and market execution. The firm’s commitment to enhancing therapeutic outcomes for cancer patients is apparent in its ongoing clinical studies and innovative research efforts.

The announcement of this employee inducement grant is more than just a standard operating procedure; it signifies ADC Therapeutics’ commitment to investing in its people. By empowering employees through such initiatives, the company reinforces its ethos of nurturing talent and driving the collective mission towards excellence in therapeutic advancements.

This development highlights how crucial a motivated workforce is in the competitive landscape of pharmaceutical development. Engaging and retaining skilled professionals aligns with ADC Therapeutics’ broader goals of enhancing treatment options and ultimately improving survival outcomes for patients worldwide. As the company continues to pioneer advancements in antibody-drug conjugate technology, initiatives like this grant will play a pivotal role in sustaining its operational excellence and innovative momentum.

For further information on ADC Therapeutics and its groundbreaking therapies, including ZYNLONTA, you can visit their official website or connect on LinkedIn. ADC Therapeutics is keen on establishing itself as a trusted name in oncology, tirelessly working to make a tangible difference in patients' lives.